BioGaia’s results for the first quarter to exceed market expectations
(Figures in the brackets refer to the same period the previous year) During the first quarter of 2023, BioGaia's sales have been impacted by increased demand, mainly in the Americas and APAC. The sales in Americas have also been positively impacted by certain one-time effects related to BioGaia starting to sell through its own subsidiary, BioGaia Canada. The sales in APAC have been positively impacted by effects related to the removal of covid restrictions in China. For the first quarter, sales are preliminarily estimated at SEK 366 million (284), an increase of 29% (excluding foreign